Recent Articles from GlobeNewswire

VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)

Fans Can Celebrate the Return of X-Men ’97 with a Dave’s #4 Meal, Blind-Bag Collectible Figurine, and App-Exclusive Pins and Comics

SEAL BEACH, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Diversified Technical Systems, Inc. (DTS), a VPG company and leading manufacturer of data acquisition systems and sensors for crash safety testing, has been named the 2026 Supplier of the Year by Automotive Testing Technology International (ATTI). The award was presented at the 2026 ATTI Awards ceremony on June 24th at Automotive Testing Expo Europe in Stuttgart, Germany.

THORNTON, Colo., June 29, 2026 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (“Ascent” or the “Company”) (Nasdaq: ASTI), the leading U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today announced the results of its preliminary Atomic Oxygen (AO) exposure testing for its space grade thin-film PV products. Testing has shown significant resilience to Atomic Oxygen in Low-Earth Orbit (LEO).

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution.

Index inclusion expands visibility with institutional investors, and passive index funds

Ahead of the nation’s 250th anniversary, most adults 21+ say beer is as American as apple pie

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Biogen, Inc. (NASDAQ: BIIB):

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million.

WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.

NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026.

Roadzen Posts First ‘Rule of 40’ Quarter in Two Years; FY2026 Net Loss Narrows 69% and Adjusted EBITDA Loss Improves 58%, with Seventh Straight Quarter of Adjusted EBITDA Gains Nearing Breakeven

Veteran public-company CFO joins Pasqal to lead its planned Nasdaq listing and scale the commercial deployment of neutral-atom quantum computing

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in our global program, evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

MONTREAL, June 29, 2026 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, has released its 2025 Corporate Sustainability Report, highlighting continued progress in environmental performance and responsible operations across its global business.

HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- HyOrc Corporation (OTCQB: HYOR), a developer of advanced waste-to-methanol infrastructure, today announced it has been formally profiled by Lux Research, a premier provider of tech-enabled research and advisory services for institutional and industrial sectors.

BOCA RATON, FL, June 29, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that DeFi Development Corporation UK PLC (“DFDV UK”) is no longer affiliated with the Company’s treasury accelerator strategy.

Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has been egranted an additional U.S. Patent, No. 12,357,590, titled "BINGE BEHAVIOR REGULATORS", by the United States Patent and Trademark Office (USPTO).

Four of Five Directors Would Have Lost Without Shares Issued to Themselves Weeks Before the Vote

- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New Drug Application in 20281,2,3 -

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer.

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted

Highlights

DANBURY, Conn., June 29, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) announced that the Board of Directors of the Export-Import Bank of the United States (EXIM) approved a financing package on June 23, 2026, of $49 million to be disbursed in two tranches.

Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions

BEIJING, June 29, 2026 (GLOBE NEWSWIRE) -- According to the press conference for Global Digital Economy Conference 2026 (GDEC 2026) held on June 25, the conference will take place from July 2 to 5. Under the theme "Building Digital-Friendly Cities -- Digital Intelligence without Boundaries," it will focus on core issues in key areas such as artificial intelligence, digital governance, and data elements. With nearly 40 high-level delegations and over 1,000 distinguished guests from around the world, the conference aims to promote the sharing of digital innovation achievements and mutual trust in digital governance, presenting a brand-new digital feast to the global audience.

Unaccountable Board Led by Chair & Interim CEO Leslie C.G. Campbell Continues to Preside Over Stunning Destruction of Stockholder Value

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Keel Infrastructure Corp. (Nasdaq: KEEL; TSX: KEEL) (“Keel Infrastructure” or “Keel”), a North American digital infrastructure and energy company, has been added as a member of the broad-market Russell 3000® Index, effective as of U.S. market open today, as part of the first 2026 Russell indexes reconstitution.

Sinhala commentary and a globally stacked player pool set the stage for LPL’s strongest regional and international season yet

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) (“IREN”) today announced that it has been added to the Russell 1000 Index effective after market close on June 26, following the FTSE Russell Indexes reconstitution.

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 

HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Kirby Corporation ("Kirby") (NYSE: KEX) will announce its 2026 second quarter results at 6:00 a.m. Central Daylight Time (“CDT”) on Wednesday, July 29, 2026. This announcement will be followed by an earnings conference call webcast at 7:30 a.m. CDT.

SINGAPORE, June 29, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, today announced that its AI-first customer engagement platform, EngageLab, officially launched "Silent Auth", an advanced passwordless authentication solution designed to complement existing SMS OTP services and elevate identity verification for the global market.

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution.

CHICAGO, June 29, 2026 (GLOBE NEWSWIRE) -- Amplify ETFs announces June income distributions for its income ETFs.

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Lagniappe Labs LLC, provider of the Prime Unicorn™ Index family, including the Prime Unicorn™ Composite Index and the Prime Unicorn™ 30 Index, today announced that it has licensed the Prime Unicorn™ 30 Index to RiverNorth Capital Management, LLC (“RiverNorth”) for use in innovative closed-end funds. This licensing agreement enables RiverNorth to launch funds that seek to provide investors with exposure to the performance of top U.S. venture-backed private companies valued at $1 billion or more, commonly known as unicorns.The Prime Unicorn™ Composite Index, first launched in 2017, is the leading benchmark for U.S. venture-backed unicorns. It is a modified market capitalization index that tracks the share price performance of private U.S. companies valued at $1 billion or higher. Drawing from both primary financing rounds and secondary market data, the index currently includes 225 components and offers daily tracking, serving as a tool for financial product creation, performance benchmarking, competitive intelligence, and fair value assessments. The Prime Unicorn™ 30 Index, a focused subset, measures the performance of the 30 highest-valued unicorns, providing targeted exposure to market leaders in disruptive technologies and emerging industries.Under the agreement, RiverNorth has licensed the Prime Unicorn™ 30 Index for its creation of listed closed-end funds, including the RiverNorth Long Prime Unicorn Fund I, Inc. and RiverNorth Short Prime Unicorn Fund I, Inc. (both pending regulatory approval). “This licensing marks an exciting milestone in making private market exposure more accessible to a broader range of investors,” said Ross Barrett, Co-Founder of Lagniappe Labs LLC. “RiverNorth's expertise in closed-end funds aligns perfectly with our mission to provide transparent, data-driven benchmarks for unicorn investments. We're thrilled to partner with them to bring this innovative product to market.”RiverNorth Capital Management, LLC, a pioneer in closed-end fund strategies, specializes in opportunistic investments across alternative asset classes. With this licensing, RiverNorth continues its tradition of offering unique vehicles that bridge public and private markets, designed to allow investors to gain synthetic exposure to high-growth private companies without direct venture capital commitments.For more information on the Prime Unicorn Index, visit www.primeunicornindex.com. Details on RiverNorth's funds can be found in their SEC filings, and by visiting www.rivernorth.com/unicornfunds                                                                                                            About Lagniappe Labs LLC and the Prime Unicorn Index FamilyLagniappe Labs LLC owns and maintains the Prime Unicorn Index family, a leading benchmark for U.S. unicorn companies. Launched by a team with extensive experience in venture capital valuations, the index supports financial innovation and provides insights into private market dynamics. For licensing opportunities, email contact@primeunicornindex.com.About RiverNorth Capital Management, LLCRiverNorth Capital Management, LLC is an independent investment manager and closed-end fund expert specializing in opportunistic strategies and structures built to exploit market inefficiencies. Founded in 2000, RiverNorth manages $4.9 billion of assets in registered funds, private funds and separately managed accounts. Visit www.rivernorth.com for more information.

—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—

Unites Rocket Lab's leading launch and satellite manufacturing capabilities with Iridium's global network, spectrum, and experience to unlock critical space applications.

SINGAPORE, June 29, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) ("Bitdeer" or the "Company"), a world-leading technology company for AI and Bitcoin mining infrastructure, today announced that its wholly-owned subsidiary, Tydal Data Center AS, has executed a colocation lease agreement (the "Lease") for its Tydal, Norway AI data center site. The Lease has not yet become effective and remains subject to the satisfaction of certain conditions precedent beyond Bitdeer's control, including the completion of certain external customer and supplier arrangements by the counterparty. There is no assurance that such conditions will be satisfied, or that the Lease will become effective.

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Surge Energy Inc. (TSX: SGY; OTCQX: SGYEF), an oil focused E&P company, has qualified to trade on the OTCQX® Best Market. Surge Energy Inc. upgraded to OTCQX from the Pink Limited™ Market.

Japan’s coconut pioneer just landed in America — and she’s resetting the butter aisle. Better Than Butter® launches on Misfits Market, West Coast first, expanding nationwide by year-end.

CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference (AAIC) 2026, taking place July 12-15 in London, UK. Presentations will include data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of LEQEMBI® (lecanemab).

Golar LNG's 2nd Quarter 2026 results will be released before the market opens on Thursday, August 13, 2026. In connection with this a webcast presentation will be held at 08:00am Eastern Time (1:00pm London Time) on Thursday August 13, 2026. The presentation will be available to download from the Investor Relations section at www.golarlng.com

New AI-native platform draws on 20+ years of proprietary energy data and was built and refined through a pilot program with 78 client companies

Nate Baxter Appointed President and Chief Executive Officer 

INDIANAPOLIS, June 29, 2026 (GLOBE NEWSWIRE) -- Kite Realty Group (NYSE: KRG) (the “Company”) announced today that its operating partnership, Kite Realty Group, L.P. (the “Operating Partnership”), launched an offering (the “Offering”), subject to market conditions and other factors, of $300 million aggregate principal amount of exchangeable senior notes due 2032 (the “Notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Operating Partnership also intends to grant the initial purchasers of the Notes an option to purchase up to an additional $45 million aggregate principal amount of Notes.

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- FTAI Infrastructure Inc. (NASDAQ: FIP) (the “Company” or “FIP”) announced today that it has completed the acquisition of AP Shale Logistics ManagementCo LLC, doing business as Tidewater Logistics (“Tidewater”), a barge and rail transloading company with operations in Ohio, West Virginia, and Texas. The Company acquired Tidewater for a cash consideration of approximately $45 million, funded through an upsizing of FIP’s existing term loan with existing lenders.

Integration with Saber Money brings India rupee payout and Eurozone and UK payment access to OwlPay Harbor, opening a near real-time settlement path into one of the world’s largest cross-border payment markets

First concentrate production is a major milestone in the restart of the USA’s newest silver-zinc-lead mine

LOUISVILLE, Ky., June 29, 2026 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “we,” “us,” “our,” or the “Company”), a leading provider of digital signage, media and AdTech solutions, today announced that it has commenced an underwritten offering of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 12.5% of the total number of shares of common stock offered in the public offering (including shares issuable upon exercise of the pre-funded warrants). The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

Goranson Bain Ausley has been named one of the Austin Business Journal's Best Places to Work for 2026, marking the firm's third consecutive year receiving the recognition

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH); a biopharmaceutical company focused on delivering Medicines that Make a Difference® in people’s lives. This proposed acquisition adds YUPELRI®, the first and only nebulized, once-daily, long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD), to Zymeworks’ partnered portfolio, furthering the Company's commitment to improving outcomes for patients with serious diseases.

PARIS, June 29, 2026 (GLOBE NEWSWIRE) -- Constellium SE (NYSE: CSTM) announced today that it sold its ownership stake in its automotive structures joint venture in Changchun, China, together with its partner, to a Chinese automotive holding company.

TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- McEwen Inc. (NYSE/TSX: MUX) today announced that it has been added to the Russell 2000® Index as part of the June 2026 Russell Reconstitution. The reconstitution becomes effective upon the opening of US equity markets on June 29, 2026. Membership in the Russell 2000® Index is based on inclusion in the broad-market Russell 3000® Index.

Establishes Kandi's entry into backup power and energy storage solutions for rapidly-growing AI data center market

Garching/Munich and Münster, Germany - June 29, 2026 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the University of Münster today announced updated preliminary results from a Phase 1 clinical trial of investigational candidate, ITM-31 (177Lu-6A10-Fab), an intracavitary targeted radiotherapy, in patients with glioblastoma. These data showed a manageable safety profile, with all patients remaining alive since enrollment began in January 2024. Enrollment is now complete, and the initial six-month follow-up period for all patients is expected to be completed by the end of 2026. Preliminary data were recently presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium, in Vienna, Austria.The investigator-initiated Phase 1 trial (NCT05533242) is a prospective, single-arm, multicenter, dose-escalation study evaluating the safety, tolerability, and maximum tolerated dose of ITM-31, as well as progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed glioblastoma, following surgical resection and standard radio-chemotherapy, with no or minimal residual disease. ITM-31 is designed as a maintenance therapy applied during a period of stability. The study enrolled ten patients across four clinical sites at German university hospitals in Münster, Würzburg, Essen, and Cologne.ITM-31 is a Lutetium-177-labeled 6A10 Fab fragment targeting carbonic anhydrase XII (CA XII), a cell surface protein expressed in more than 90% of glioblastoma cases but absent in healthy brain tissue. It is administered via intracavitary injection directly into the post-surgical resection cavity, enabling targeted radiation of residual tumor cells, bypassing the blood–brain barrier. Under a licensing agreement with Helmholtz Munich, ITM holds exclusive rights to develop and commercialize ITM-31.“By delivering ITM-31 directly into the surgical resection cavity, our goal is to achieve high targeted radiation exposure at the site of residual disease, while minimizing systemic toxicity,” said Dr. Michael Müther, study investigator and neurosurgeon at the University of Münster. “Given the disease’s high rate of recurrence, strategies that address residual tumor cells locally may play an important role in improving outcomes.”“We have come a long way from validating our antibody in the first cell assays to bringing it into the clinic. It has been a wonderful experience to partner with the University of Münster and ITM for this first study, and we are hopeful that this approach may ultimately benefit patients with glioblastoma,” said Prof. Reinhard Zeidler, group leader at the Institute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Munich, who identified and developed the CA XII-targeting 6A10 antibody fragment used in ITM-31.Study design:

HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- KBR (NYSE: KBR) has been selected to provide technology licensing and Front-End Engineering Design (FEED) services based on its PureSAF℠ technology for the proposed Sustainable Aviation Fuel (SAF) plant being developed by Keppel Ltd.’s (Keppel) Infrastructure Division and Aster Chemicals and Energy (Aster) on Singapore’s Jurong Island.

LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Emerging Markets Global Advisory LLP (EMGA) announced the successful closure of a USD 15 million senior debt facility for Citizens Development Business Finance PLC (CDB), marking a significant milestone in strengthening Sri Lanka’s financial sector and supporting sustainable growth.

Heidelberg, Germany, June 29, 2026. TolerogenixX, a clinical-stage biopharmaceutical company founded in 2016 developing personalized cell therapies to induce antigen-specific immune tolerance, today announced that the last patient has undergone kidney transplantation in TOL-2, the Company’s randomized, controlled Phase IIb clinical trial evaluating MIC-Lx in living-donor kidney transplantation (ClinicalTrials.gov identifier: NCT05365672 and EudraCT No.: 2021-000561-33).

The group behind Shop Circle launches Circeus as its holding company brand, backed by a new equity investment from the EBRD. Shop Circle continues as the group’s retail and commerce software division. The investment will accelerate the deployment of AI across the portfolio and fund the continued acquisition of the software businesses that power the everyday economy.

LEADING EDGE MATERIALS GRANTED 25-YEAR MINING LEASE FOR NORRA KÄRR HEAVY RARE EARTH ELEMENTS PROJECT

Press Release

Bernin (Grenoble), France, June 29, 2026 - Soitec, a world leader in the design and manufacturing of innovative semiconductor materials, and ZenSemi, a premier specialty foundry in China, today announced a strategic collaboration to enable high-volume production of 300mm BCD-on-SOI (Bipolar-CMOS-DMOS on Silicon-on-Insulator) technologies for next-generation power electronics powering AI datacenters, EVs, humanoid robots and industrial applications.

LONDON and NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- BT Group (BT) and Verizon Communications Inc. (NYSE, Nasdaq: VZ) today announced the signing of an agreement to combine their respective international enterprise operations into a 50:50 joint venture – in a move that is set to transform international connectivity.

PRESS RELEASE

ANTWERP, Belgium, 29 June 2026, 08:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold two Suezmaxes, generating a capital gain of approximately 100.5 million USD.

COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older.

Amsterdam, June 29, 2026

Expansion builds on successful collaboration across Latin America and reinforces commitment to advancing innovative cardiometabolic therapies across international markets

WISeKey International Holding Ltd Signs Merger Agreement to Redomicile to the British Virgin Islands

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p<0.0001), the first and only statistically significant placebo-controlled arm span result reported for an achondroplasia trial at 52 weeks